Agios Pharmaceuticals, INC Form 4 insider transactions

Tsveta Milanova, Chief Commercial Officer of Agios Pharmaceuticals, reports the acquisition and disposal of common stock related to restricted stock unit vesting.

Director David Scadden of Agios Pharmaceuticals exercised stock options and sold a portion of the acquired shares on December 11, 2024.

Theodore James Jr. Washburn, Principal Accounting Officer at Agios Pharmaceuticals, sold 772 shares of common stock at $56.09 per share.

Director Rahul Ballal exercised stock options and sold shares of Agios Pharmaceuticals (AGIO) on November 7th and 8th, 2024, under a pre-arranged trading plan.

James William Burns, Chief Legal Officer of Agios Pharmaceuticals, sold shares of common stock on November 7, 2024, under a pre-arranged 10b5-1 trading plan.

Cecilia Jones, CFO of Agios Pharmaceuticals, reports the acquisition and disposal of common stock and restricted stock units.

Director Rahul Ballal reports transactions involving Agios Pharmaceuticals common stock and restricted stock units.

Director Cynthia Smith reports the acquisition and disposal of Agios Pharmaceuticals common stock and restricted stock units on August 11, 2024.

Brian Goff, CEO of Agios Pharmaceuticals, reports the acquisition and disposal of common stock and restricted stock units on August 8, 2024.

Chief Medical Officer Sarah Gheuens reports acquisition and disposal of Agios Pharmaceuticals stock related to vesting of restricted stock units.

Director Jacqualyn Fouse reports acquisition of stock options and restricted stock units in Agios Pharmaceuticals.

Director Cynthia Smith reports acquisition of restricted stock units and stock options in Agios Pharmaceuticals.

Director Jeffrey Capello reports acquisition of stock options and restricted stock units in Agios Pharmaceuticals.

Director Rahul Ballal reports acquisition of restricted stock units and stock options in Agios Pharmaceuticals.

Director Kaye Foster-Cheek reports acquisition of stock options and restricted stock units in Agios Pharmaceuticals.

Director Maykin Ho reported the acquisition of restricted stock units and stock options in Agios Pharmaceuticals on June 20, 2024.

Director Catherine Owen reports acquisition of stock options and restricted stock units in Agios Pharmaceuticals.

Director David Schenkein reports the acquisition of restricted stock units and stock options in Agios Pharmaceuticals.

Director David Scadden reports the acquisition of restricted stock units and stock options in Agios Pharmaceuticals.

Kaye Foster-Cheek, a director of Agios Pharmaceuticals, reports the vesting of restricted stock units, a gift of shares to a non-profit, and transactions affecting her beneficial ownership of the company's common stock.

Director Jacqualyn Fouse reported a transaction involving Agios Pharmaceuticals common stock on June 13, 2024, according to a Form 4 filing with the SEC.

Director David P. Schenkein exercised restricted stock units to acquire 3,388 shares of Agios Pharmaceuticals common stock on June 13, 2024.

Director Rahul Ballal reports vesting of restricted stock units into common stock of Agios Pharmaceuticals.

Director Cynthia Smith reports the vesting of restricted stock units and subsequent disposal of shares on June 13, 2024.

Director Maykin Ho reports acquisition and disposal of Agios Pharmaceuticals common stock and restricted stock units on June 13, 2024.

Director David Scadden reports the vesting and subsequent disposal of restricted stock units in Agios Pharmaceuticals.

Director Catherine Owen reports the vesting of restricted stock units in Agios Pharmaceuticals.

Director Jeffrey Capello reports the vesting of restricted stock units into common stock of Agios Pharmaceuticals.

CEO Brian Goff of Agios Pharmaceuticals sold shares to cover tax obligations after performance share units vested, while also acquiring shares through the vesting of these units.

The Principal Accounting Officer of Agios Pharmaceuticals, Theodore James Jr. Washburn, sold 1,362 shares of common stock on June 3, 2024.